These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35701753)

  • 1. Mobility test to assess functional vision in dark-adapted patients with Leber congenital amaurosis.
    Roman AJ; Cideciyan AV; Wu V; Mascio AA; Krishnan AK; Garafalo AV; Jacobson SG
    BMC Ophthalmol; 2022 Jun; 22(1):266. PubMed ID: 35701753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome measure for the treatment of cone photoreceptor diseases: orientation to a scene with cone-only contrast.
    Roman AJ; Cideciyan AV; Matsui R; Sheplock R; Schwartz SB; Jacobson SG
    BMC Ophthalmol; 2015 Aug; 15():98. PubMed ID: 26253563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient pupillary light reflex in CEP290- or NPHP5-associated Leber congenital amaurosis: Latency as a potential outcome measure of cone function.
    Krishnan AK; Jacobson SG; Roman AJ; Iyer BS; Garafalo AV; Héon E; Cideciyan AV
    Vision Res; 2020 Mar; 168():53-63. PubMed ID: 32088401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full-Field Pupillary Light Responses, Luminance Thresholds, and Light Discomfort Thresholds in CEP290 Leber Congenital Amaurosis Patients.
    Collison FT; Park JC; Fishman GA; McAnany JJ; Stone EM
    Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7130-6. PubMed ID: 26529047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures.
    Roman AJ; Schwartz SB; Aleman TS; Cideciyan AV; Chico JD; Windsor EA; Gardner LM; Ying GS; Smilko EE; Maguire MG; Jacobson SG
    Exp Eye Res; 2005 Feb; 80(2):259-72. PubMed ID: 15670804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Natural History of Leber Congenital Amaurosis and Cone-Rod Dystrophy Associated with Variants in the GUCY2D Gene.
    Hahn LC; Georgiou M; Almushattat H; van Schooneveld MJ; de Carvalho ER; Wesseling NL; Ten Brink JB; Florijn RJ; Lissenberg-Witte BI; Strubbe I; van Cauwenbergh C; de Zaeytijd J; Walraedt S; de Baere E; Mukherjee R; McKibbin M; Meester-Smoor MA; Thiadens AAHJ; Al-Khuzaei S; Akyol E; Lotery AJ; van Genderen MM; Ossewaarde-van Norel J; van den Born LI; Hoyng CB; Klaver CCW; Downes SM; Bergen AA; Leroy BP; Michaelides M; Boon CJF
    Ophthalmol Retina; 2022 Aug; 6(8):711-722. PubMed ID: 35314386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Potential for Macular Cone Vision in Leber Congenital Amaurosis Due to CEP290 or NPHP5 Mutations: Predictions From Artificial Intelligence.
    Sumaroka A; Garafalo AV; Semenov EP; Sheplock R; Krishnan AK; Roman AJ; Jacobson SG; Cideciyan AV
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2551-2562. PubMed ID: 31212307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome Measures for Clinical Trials of Leber Congenital Amaurosis Caused by the Intronic Mutation in the CEP290 Gene.
    Jacobson SG; Cideciyan AV; Sumaroka A; Roman AJ; Charng J; Lu M; Choi W; Sheplock R; Swider M; Kosyk MS; Schwartz SB; Stone EM; Fishman GA
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2609-2622. PubMed ID: 28510626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Outcomes for Clinical Trials of Leber Congenital Amaurosis Caused by GUCY2D Mutations.
    Jacobson SG; Cideciyan AV; Sumaroka A; Roman AJ; Charng J; Lu M; Choudhury S; Schwartz SB; Heon E; Fishman GA; Boye SE
    Am J Ophthalmol; 2017 May; 177():44-57. PubMed ID: 28212877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leber Congenital Amaurosis Due to
    Jacobson SG; Cideciyan AV; Sumaroka A; Roman AJ; Wu V; Swider M; Sheplock R; Krishnan AK; Garafalo AV
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy.
    Cideciyan AV; Rachel RA; Aleman TS; Swider M; Schwartz SB; Sumaroka A; Roman AJ; Stone EM; Jacobson SG; Swaroop A
    Hum Mol Genet; 2011 Apr; 20(7):1411-23. PubMed ID: 21245082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapy.
    Boye SE; Huang WC; Roman AJ; Sumaroka A; Boye SL; Ryals RC; Olivares MB; Ruan Q; Tucker BA; Stone EM; Swaroop A; Cideciyan AV; Hauswirth WW; Jacobson SG
    PLoS One; 2014; 9(3):e92928. PubMed ID: 24671090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations.
    Jacobson SG; Aleman TS; Cideciyan AV; Roman AJ; Sumaroka A; Windsor EA; Schwartz SB; Heon E; Stone EM
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2368-75. PubMed ID: 19117922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fleck-like lesions in
    Aleman TS; O'Neil EC; Uyhazi KE; Parchinski KM; Santos AJ; Weber ML; Colclough SP; Billek AS; Zhu X; Leroy BP; Bedoukian EC
    Ophthalmic Genet; 2022 Dec; 43(6):824-833. PubMed ID: 36469661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis.
    Pasadhika S; Fishman GA; Stone EM; Lindeman M; Zelkha R; Lopez I; Koenekoop RK; Shahidi M
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2608-14. PubMed ID: 19959640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.
    Li S; Samardzija M; Yang Z; Grimm C; Jin M
    J Neurosci; 2016 May; 36(21):5808-19. PubMed ID: 27225770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electroretinographic abnormalities in parents of patients with Leber congenital amaurosis who have heterozygous GUCY2D mutations.
    Koenekoop RK; Fishman GA; Iannaccone A; Ezzeldin H; Ciccarelli ML; Baldi A; Sunness JS; Lotery AJ; Jablonski MM; Pittler SJ; Maumenee I
    Arch Ophthalmol; 2002 Oct; 120(10):1325-30. PubMed ID: 12365911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded Retinal Disease Spectrum Associated With Autosomal Recessive Mutations in GUCY2D.
    Stunkel ML; Brodie SE; Cideciyan AV; Pfeifer WL; Kennedy EL; Stone EM; Jacobson SG; Drack AV
    Am J Ophthalmol; 2018 Jun; 190():58-68. PubMed ID: 29559409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEP290 Mutation Spectrum and Delineation of the Associated Phenotype in a Large German Cohort: A Monocentric Study.
    Feldhaus B; Weisschuh N; Nasser F; den Hollander AI; Cremers FPM; Zrenner E; Kohl S; Zobor D
    Am J Ophthalmol; 2020 Mar; 211():142-150. PubMed ID: 31734136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full-field stimulus testing: Role in the clinic and as an outcome measure in clinical trials of severe childhood retinal disease.
    Roman AJ; Cideciyan AV; Wu V; Garafalo AV; Jacobson SG
    Prog Retin Eye Res; 2022 Mar; 87():101000. PubMed ID: 34464742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.